Glenmark Pharma's Q2FY19 results were a beat, Sales/EBITDA/APAT at Rs25.8bn/Rs4.4bn/Rs2.5bn were 19.5%/12.5%/39.6% above our expectations. Except LATAM all regions had a strong traction. We expect Glenmark's sales/EBITDA/net profit...